About Neurotensin receptor type 1
Neurotensin receptor type 1 (NTSR1) is a protein
from Homo sapiens identified by UniProt accession
P30989, 418 residues long.
MolForge cross-references it against 0 known binders and
229 disease associations.
Target properties
| Protein name | Neurotensin receptor type 1 |
| UniProt accession | P30989 |
| Gene | NTSR1 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (229)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.28
- PHF-tau measurement · score 0.27
- C-reactive protein measurement · score 0.27
- breast adenocarcinoma · score 0.25
- low density lipoprotein cholesterol measurement · score 0.24
- head and neck squamous cell carcinoma · score 0.17
- low grade glioma · score 0.14
- adolescent idiopathic scoliosis · score 0.13
- serum gamma-glutamyl transferase measurement · score 0.13
- Cough · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30989-F1 | alphafold | PREDICTED | 79.62 | — |
Amino-acid sequence (418 residues)
MRLNSSAPGT PGTPAADPFQ RAQAGLEEAL LAPGFGNASG NASERVLAAP SSELDVNTDI YSKVLVTAVY LALFVVGTVG NTVTAFTLAR KKSLQSLQST VHYHLGSLAL SDLLTLLLAM PVELYNFIWV HHPWAFGDAG CRGYYFLRDA CTYATALNVA SLSVERYLAI CHPFKAKTLM SRSRTKKFIS AIWLASALLA VPMLFTMGEQ NRSADGQHAG GLVCTPTIHT ATVKVVIQVN TFMSFIFPMV VISVLNTIIA NKLTVMVRQA AEQGQVCTVG GEHSTFSMAI EPGRVQALRH GVRVLRAVVI AFVVCWLPYH VRRLMFCYIS DEQWTPFLYD FYHYFYMVTN ALFYVSSTIN PILYNLVSAN FRHIFLATLA CLCPVWRRRR KRPAFSRKAD SVSSNHTLSS NATRETLY
Explore Neurotensin receptor type 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets